Artwork

Content provided by Liberum IME. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Liberum IME or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

Personalizing care in thyroid cancer using molecular tumor boards

16:52
 
Distribuie
 

Manage episode 342696733 series 3304844
Content provided by Liberum IME. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Liberum IME or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

In today’s episode, we welcome Principal Researcher Dr. David Tamborero who was integral to the development of the Molecular Tumor Board Portal to discuss the benefits associated with molecular tumor boards and the way in which the portal can support the discussions that take place at tumor board meetings, as well as how these initiatives can support the management of patients with thyroid cancer.

References

  1. Larson KL et al. Clinical Outcomes of Molecular Tumor Boards: A Systematic Review.
    JCO Precis Oncol 2021;5:PO.20.00495
  2. Capdevila J et al. Molecular diagnosis and targeted treatment of advanced follicular
    cell-derived thyroid cancer in the precision medicine era. Cancer Treat Rev 2022;106:102380
  3. Mahmood U and Lorch JH. Precision Medicine in Aggressive Thyroid Cancer: Moving Beyond Multitargeted Tyrosine Kinase Inhibitors. Cancer Cytopathol 2022;130:8–11
  4. VanderWalde A et al. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. J Pers Med 2020;10:252
  5. Tamborero D et al. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer 2022;3:251–261

Target Audience:

Oncologists, pathologists and other HCPs involved in the diagnosis of RET and TRK cancers, with a focus on community practitioners.

Learning Objective:

  1. Recall thyroid RET and TRK fusion-positive cancer diagnosis and relevant genomic testing guidelines and identify ways to adapt the guidelines to local settings
  2. Discuss “precision medicine” and new technologies, including “liquid biopsy”
  3. Review the organisation of care and strategies for more efficient care delivery

These learning objectives are for the podcast series. This episode focuses on the second and third objective.

Funding Information:

This episode is supported by an educational grant from Eli Lilly, who have had no influence on the content or choice of faculty.

Staff Disclosure:

Dr. David Tamborero has no relevant disclosures to announce

  continue reading

32 episoade

Artwork
iconDistribuie
 
Manage episode 342696733 series 3304844
Content provided by Liberum IME. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Liberum IME or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

In today’s episode, we welcome Principal Researcher Dr. David Tamborero who was integral to the development of the Molecular Tumor Board Portal to discuss the benefits associated with molecular tumor boards and the way in which the portal can support the discussions that take place at tumor board meetings, as well as how these initiatives can support the management of patients with thyroid cancer.

References

  1. Larson KL et al. Clinical Outcomes of Molecular Tumor Boards: A Systematic Review.
    JCO Precis Oncol 2021;5:PO.20.00495
  2. Capdevila J et al. Molecular diagnosis and targeted treatment of advanced follicular
    cell-derived thyroid cancer in the precision medicine era. Cancer Treat Rev 2022;106:102380
  3. Mahmood U and Lorch JH. Precision Medicine in Aggressive Thyroid Cancer: Moving Beyond Multitargeted Tyrosine Kinase Inhibitors. Cancer Cytopathol 2022;130:8–11
  4. VanderWalde A et al. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. J Pers Med 2020;10:252
  5. Tamborero D et al. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer 2022;3:251–261

Target Audience:

Oncologists, pathologists and other HCPs involved in the diagnosis of RET and TRK cancers, with a focus on community practitioners.

Learning Objective:

  1. Recall thyroid RET and TRK fusion-positive cancer diagnosis and relevant genomic testing guidelines and identify ways to adapt the guidelines to local settings
  2. Discuss “precision medicine” and new technologies, including “liquid biopsy”
  3. Review the organisation of care and strategies for more efficient care delivery

These learning objectives are for the podcast series. This episode focuses on the second and third objective.

Funding Information:

This episode is supported by an educational grant from Eli Lilly, who have had no influence on the content or choice of faculty.

Staff Disclosure:

Dr. David Tamborero has no relevant disclosures to announce

  continue reading

32 episoade

Todos os episódios

×
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință